Skip to main content

Search

Reset all filters
826 Result(s)
Sort by

Yamagata

Yamagata

With its location in the Yamagata prefecture (Higashine), this site focuses on the production & packaging of human pharmaceuticals for the Japanese market.
Xochimilco

Xochimilco

With its presence in Greece of more than a half century,
Shanghai

Shanghai

Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Clinical Trials

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
Laura loves her diverse career

Laura loves her diverse career

Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Confronting health disparities in clinical trials

Confronting health disparities in clinical trials

As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
Koropi

Koropi

With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Kobe

Kobe

The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Ingelheim

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Clinical Pharmacology

Clinical Pharmacology

Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Our Commitment

Our Commitment

Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d